References
- Holcslaw T. L., Beck T. R. Clinical experience with intravenous fenoldopam. Am. J. Hypertens 1990; 3(6)120s–125s
- Nichols A. J., Ruffolo R. R., Jr, Brooks D. P. The pharmacology of fenoldopam. Am. J. Hypertens 1990; 3(6)116s–119s
- Blanchett D. G., Green J. A., Nara A., Pospisil R., Robert R. C., Kasmer R. J., Boyle D. A., Cyronak M. J., Corder C. N. The effect of food on pharmacokinetics of fenoldopam in class III heart failure. Clin. Pharmacol. Ther. 1991; 49(4)449–56
- Ziemniak J. A., Boppana V. K., Cyronak M. J., Stote R. M. A retrospective analysis of fenoldopam renal excretion in 65 subjects: Evidence for possible intrarenal formation of fenoldopam from metabolites. Pharm. Res. 1989; 6(8)702–705
- Dent J., Lynn R. K., Roman R. Summary of fenoldopam pharmacokinetics and information in support of fenoldopam controlled release formulations. SB Pharmaceuticals internal documents 1987
- Timko R. J., Lordi N. G. In vitro evaluation of three commercial sustained release papaverine hydrochloride products. J. Pharm. Sci. 1978; 67: 496
- Beechgaard H., Beggesen S. Propoxyphene and nor-propoxyphene: Influence of type of controlled release formulation on intra-and intersubject variations. J. Pharm. Sci. 1980; 69: 1327
- Thoma K., Zirnmer T. Retardation of weak basic drugs: Improvement of availability-problems with nos-capine in diffusion pellets. Pharm. Ind. 1989; 51(1)98–101
- Thoma K., Zimmer T. Retardation of weakly basic drugs with diffusion tablets. Int. J. Pharm. 1990; 58: 197–202
- Thoma K., Knott F. Retardation of weakly basic drugs: Improvement in the release of dihydroergotamine methane sulfonate from diffusion dosage forms. Pharm. Ind. 1991; 53(7)686–690
- Gabre K. E. Effect of organic acids on the release patterns of weakly basic drugs from inert sustained matrix tablets. Eur. J. Pharm. Biopharm. 1992; 38(6)192–202
- Gruber P., Brickl R., Bozier G., Stricker H. Dipyri-camole sustained release forms comprising lacquer coated particles and the preparation thereof. 1983, U.S. Patent 4,367,217
- Panoz D. E., Geoghegan E. J. Controlled absorption diltiazen pharmaceutical formulation. 1988, U.S. Patent 4,721,619
- Doherty C., York P. Microenvironmental pH control of drug dissolution. Int. J. Pharm. 1989; 50: 223–232
- Gabr K. E. Effect of organic acids on the release patterns of weakly basic drugs from inert sustained release matrix tablets. Eur. J. Pharm. Biopharm. 1992; 38(6)199–202
- Pagay S. N. Use of buffers in matrix capsule formulations. Drug. Dev. Ind. Pharm. 1988; 14(7)875–894
- Lehmann K. Practical course in film coating of pharmaceutical dosage forms with EudragitB, Pharma Polymers, a Company of the Huls Group. 1996